Redeye: Fluoguide Q4 2023 - Bright prospects
Redeye comments on Fluoguide’s Q4 2023 report, with the company having recently communicated a strategy update. We believe the company’s new strategy is value-accretive overall, though it likely delays a potential market approval for FG001 by c6-12 months. We do some housekeeping in our model and leave our estimates and valuation largely unchanged.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/